Since more than half of HCC patients have EGFR overexpression and abnormal activation [77], the combination of the EGFR inhibitor with HCC conventional chemotherapy agents are potential strategies to improve efficacy to treatment [81]. Here, EGFR is linked to hepatocellular carcinoma.